Structural Formula (Image 1)
Chemical structure of Methylphenidate Hydrochloride displayed as a molecular diagram with labeled functional groups and atoms.*
Methylphenidate Hydrochloride Tablet, Film Coated, Extended Release
Product Images NDC 62037-725
8 FDA label images from Actavis Pharma, Inc. · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Methylphenidate Hydrochloride (NDC 62037-725). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Actavis Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure1 (Image 2)
A pharmacokinetic line graph comparing mean plasma methylphenidate concentration (ng/mL) over time (hours) for two dosing regimens: Methylphenidate HCl extended-release 18 mg once daily and Methylphenidate 5 mg three times daily. The graph shows concentration fluctuations and decline up to 32 hours post-dose.*
Figure2 (Image 3)
A bar chart comparing maximum symptoms of inattention/overactivity scale between Methylphenidate HCl extended-release tablets once daily and placebo across three studies. The vertical axis measures symptoms from no symptoms (0) to maximum symptoms (15), and the horizontal axis represents Study 1, Study 2, and Study 3 (Week 4) with respective sample sizes. Methylphenidate HCl groups show lower symptom bars than placebo groups in all studies.*
Figure 3 (Image 4)
Line graph depicting the combined attention subscale scores over 12 hours post initial dose, comparing Methylphenidate Hydrochloride extended-release tablets once daily with placebo. The vertical axis measures attention from more attentive (0.0) to less attentive (3.0). The horizontal axis shows hours post initial dose from 1 to 12. Data points for both groups include sample sizes, with mean and standard error of the mean indicated.*
1 (Image 5)
Label of Methylphenidate Hydrochloride Extended-Release Tablets, USP, 18 mg, by Teva Pharmaceuticals. The film-coated, extended-release tablets are prescription only, packaged as 100 tablets. The label includes storage instructions, dosage information, and barcode, along with a note to dispense the medication guide.*
1 (Image 6)
The label for Once-Daily Methylphenidate Hydrochloride Extended-Release Tablets, USP, showing 27 mg strength. The label indicates the product is a prescription drug with 100 tablets, distributed by Teva Pharmaceuticals. Storage instructions, medication guide directive, barcode, and serialization coding area are also visible.*
1 (Image 7)
Label for Methylphenidate Hydrochloride Extended-Release Tablets USP, 36 mg, film-coated tablet, extended release, in a package of 100 tablets. The label indicates it is for once-daily oral use and includes instructions for pharmacists to dispense the accompanying medication guide. It is manufactured for Teva Pharmaceuticals.*
1 (Image 8)
Label for Once-Daily Methylphenidate Hydrochloride Extended-Release Tablets, USP, 54 mg strength, film-coated, extended-release oral tablets. The label indicates a package size of 100 tablets, manufactured by Actavis Pharma, Inc. (Teva Pharmaceuticals). It includes usage instructions, storage conditions, and a barcode for the product.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
